Navigation Links
Clinical technique sets new standard for speed in battle to prevent pandemic infection
Date:1/25/2012

A new diagnosis technique developed by researchers at the RIKEN Omics Science Center (OSC) has succeeded in detecting influenza virus infection in only 40 minutes and with one hundred times the sensitivity of conventional methods. Clinical research conducted in 2009 and 2010 confirms the new technique accurately identified the 2009 pandemic (pdm) influenza virus in Japanese patients less than 24 hours after fever onset, much faster than standard diagnostic tests.

The human-to-human transmission of new, highly pathogenic strains of influenza virus poses today a major threat to human health and to the security of global society. With its rapid global spread, the 2009 pandemic (pdm) influenza virus reminded the world of this threat, resulting in an estimated 18,000 deaths worldwide. In Japan, infected patients over the winter season of 2009 accounted for a staggering 16% of the total population.

Tackling the challenge of such global pandemics requires new technology for rapid clinical diagnosis. To answer this need, Toshihisa Ishikawa and colleagues at the RIKEN OSC developed the RT-SmartAmp assay, a technique to rapidly detect the 2009 pdm influenza A(H1N1) virus from patient swab samples. By combining both reverse transcriptase (RT) and isothermal DNA amplification reactions in one step, the RT-SmartAmp assay does away with the need for RNA extraction and PCR reaction. The researchers adapted the RT-SmartAmp technique using a fluorescent primer to specifically detect the 2009 pdm influenza A(H1N1) virus within 40 minutes, without cross-reacting with the seasonal A(H1N1), A(H3N2), or B-type (Victoria) viruses.

The effectiveness of the RT-SmartAmp method was confirmed in clinical research carried out at Japanese hospitals during the period of October 2009 to January 2010, where it outperformed standard diagnosis tests in both speed and sensitivity. Of a total 255 clinical samples, 140 (54.9%) were identified as 2009 pdm A(H1N1)-positive by RT-SmartAmp, compared to only 110 (43.1%) detected by standard diagnostic tests. In 72.8% of all 140 infection-positive cases, the RT-SmartAmp assay detected the presence of the pdm influenza virus within 24 hours of fever onset.

Taken together, these results set a new standard for infection diagnosis speed, providing a highly-effective tool for rapidly detecting sub-types of the H5N1 virus and oseltamivir-resistant influenza viruses and promising support in the battle to prevent global pandemic infection.


'/>"/>

Contact: RIKEN Global Relations Office
gro-pr@riken.jp
RIKEN
Source:Eurekalert

Related biology technology :

1. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
2. MarketsandMarkets: Global Clinical Trial Management Systems Market Worth $1300.4 Million by 2016
3. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
4. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
5. Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis
6. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
7. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
8. NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011
9. Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation
10. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
11. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... PMG ... Trial Collaborations (CTC) conference presented by The Conference Forum in Boston on April ... they collaborate to drive improved clinical trial outcomes and bring them closer to the ...
(Date:3/27/2017)... March 27, 2017 Neurotrope, Inc. (OTCQB: ... for neurodegenerative diseases, including Alzheimer,s disease, today announced ... to list the Company,s common stock on the ... NASDAQ Stock Market, a unit of the NASDAQ ... ring the Opening Bell at the NASDAQ MarketSite ...
(Date:3/24/2017)... 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the "Company") ... China , today announced that its board of directors has ... the plan from March 27, 2017 to March 27, 2018. The amendment ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a China ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, ... elastic characteristics when deformed, which is identical to how the human discs work ... forces and return to its natural state along a hysteresis curve, exactly like ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
Breaking Biology News(10 mins):